![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RW Klecker, AG Katki and JM Collins
Division of Clinical Pharmacology, Food and Drug Administration, Rockville, Maryland 20850.
Two cell lines, U-937 and MOLT-4, were used to investigate the toxicity, DNA incorporation, and effect on mitochondria of 1-(2'-fluoro- 2'-deoxy-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) and its putative metabolite 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)-uracil (FAU). After 72-hr incubation, the IC50 values for FIAU were 6.4 microM for U- 937 cells and 26 microM for MOLT-4 cells. IC50 values for FAU were 10- fold higher in both cell lines. Incubation for 24 hr with 10 microM [2- 14C]FIAU led to 2.1% and 0.93% replacement of thymidine in DNA of U-937 and MOLT-4 cells, respectively. The predominant radioactive species measurable in DNA was FIAU. A similar incubation with [2-14C]FAU resulted in 4-fold lower DNA incorporation of a single radioactive species that coeluted with 1-(2'-fluoro-2'-deoxy-beta-D- arabinofuranosyl)-5-methyluracil (FMAU). There was no evidence of a selective repair process after DNA incorporation of FIAU or FAU (FMAU). Increased intracellular concentrations of FIAU triphosphate and incorporation into DNA were associated with an increase in cellular toxicity. Continuous exposure to a clinically achievable concentration of FIAU, 0.44 microM, produced a constant DNA incorporation of 0.80% and 0.11% for U-937 and MOLT-4 cells, respectively. FIAU was not readily metabolized to FAU or iodouracil by human liver in vitro. Compared with 2',3'-dideoxycytidine as a positive control, after 12 days of continuous exposure of U-937 and MOLT-4 cells to FIAU there was no evidence of increased lactate production. These data negate several possible mechanisms (DNA chain termination, DNA polymerase inhibition, one form of selective mitochondrial poisoning, and FAU-mediated toxicity) and provide clues for possible mechanisms (FIAU triphosphate concentration and DNA incorporation). Further work is needed to develop a complete explanation for the delayed hepatic toxicity observed in the investigational clinical trials of FIAU.
This article has been cited by other articles:
|
|
 |
|
  S. Nimmagadda, T. J. Mangner, K. A. Douglas, O. Muzik, and A. F. Shields Biodistribution, PET, and Radiation Dosimetry Estimates of HSV-tk Gene Expression Imaging Agent 1-(2'-Deoxy-2'-18F-Fluoro-{beta}-D-Arabinofuranosyl)-5-Iodouracil in Normal Dogs J. Nucl. Med., April 1, 2007; 48(4): 655 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nimmagadda, T. J. Mangner, H. Sun, R. W. Klecker Jr., O. Muzik, J. M. Lawhorn-Crews, K. A. Douglas, J. M. Collins, and A. F. Shields Biodistribution and Radiation Dosimetry Estimates of 1-(2'-Deoxy-2'-18F-Fluoro-1-{beta}-D-Arabinofuranosyl)-5-Bromouracil: PET Imaging Studies in Dogs J. Nucl. Med., November 1, 2005; 46(11): 1916 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Eiseman, C. Brown-Proctor, P. E. Kinahan, J. M. Collins, L. W. Anderson, E. Joseph, D. R. Hamburger, S.-s. Pan, C. A. Mathis, M. J. Egorin, et al. Distribution of 1-(2-Deoxy-2-fluoro-{beta}-D-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts: Rationale for Therapeutic Use and as a Positron Emission Tomography Probe for Thymidylate Synthase Clin. Cancer Res., October 1, 2004; 10(19): 6669 - 6676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lai, C.-M. Tse, and J. D. Unadkat Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs J. Biol. Chem., February 6, 2004; 279(6): 4490 - 4497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jacobs, I. Bräunlich, R. Graf, M. Lercher, T. Sakaki, J. Voges, V. Hesselmann, W. Brandau, K. Wienhard, and W.-D. Heiss Quantitative Kinetics of [124I]FIAU in Cat and Man J. Nucl. Med., March 1, 2001; 42(3): 467 - 475. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Verma, R. M. H. Schein, D. T. Jayaweera, and D. H. Kett Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy Neurology, October 1, 1999; 53(6): 1365 - 1365. [Full Text]
|
|
|
|
|
|
J. M. Collins, R. W. Klecker, and A. G. Katki Suicide Prodrugs Activated by Thymidylate Synthase: Rationale for Treatment and Noninvasive Imaging of Tumors with Deoxyuridine Analogues Clin. Cancer Res., August 1, 1999; 5(8): 1976 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. McKenzie, M. W. Fried, R. Sallie, H. Conjeevaram, A. M. Di Bisceglie, Y. Park, B. Savarese, D. Kleiner, M. Tsokos, C. Luciano, et al. Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B N. Engl. J. Med., October 26, 1995; 333(17): 1099 - 1105. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
